Weight Loss Injections and Liver Health — Australian Patient Guide

Ozempic (semaglutide 1mg weekly): TGA-approved for type 2 diabetes in Australia. Widely used off-label for weight loss, though this practice has contributed to supply shortages. PBS-subsidised for type 2 diabetes only.

Wegovy (semaglutide 2.4mg weekly): TGA-approved for chronic weight management and — since April 2026 — for MASH with moderate to advanced liver fibrosis. Private prescription, approximately $300–$395/month. PBS listing pending for eligible patients.

Mounjaro (tirzepatide weekly): TGA-approved for weight management since September 2024. Dual GLP-1/GIP receptor agonist producing 20–21% average weight loss in clinical trials. Private prescription, approximately $285–$690/month depending on dose.

All three are injectable GLP-1 receptor agonists with similar mechanisms and broadly similar liver profiles, with differences in dose, efficacy, and regulatory status.

The Beneficial Effect

All three medications produce liver benefit in patients with MASLD through the same core mechanisms:

Fat reduction: Significant weight loss — 14–21% of body weight depending on the medication and dose — preferentially reduces liver fat alongside body fat. Clinical trials consistently demonstrate 30–40% reduction in liver fat content in patients with MASLD on these medications.

Insulin sensitivity improvement: GLP-1 medications improve insulin sensitivity, reducing the metabolic stimulus that drives fat accumulation in the liver.

Direct hepatic action: Secondary analyses from the ESSENCE trial showed liver benefits beyond what weight loss alone could explain — suggesting direct anti-inflammatory and anti-fibrotic effects via GLP-1 receptors in liver tissue.

In the ESSENCE trial, 62.9% of patients on semaglutide 2.4mg achieved MASH resolution at 72 weeks. This is the evidence base behind the April 2026 TGA approval of Wegovy for liver disease treatment in Australia.

The Transient Effect During Rapid Weight Loss

During the early months on a weight loss injection — when weight loss is most rapid — the liver receives an increased influx of fatty acids from mobilised fat stores. This can temporarily elevate liver enzymes (ALT, AST). The elevation is generally self-limiting, resolving as weight loss pace slows.

This is not drug-induced liver injury. It is a physiological response to rapid fat mobilisation — the same phenomenon observed with very low calorie diets and bariatric surgery.

Australian Prescriber published a 2026 update recommending that adults with obesity, type 2 diabetes, or other metabolic risk factors be assessed for MAFLD, with management including noninvasive testing for liver fibrosis and addressing health risk behaviours.

This applies directly to anyone starting a weight loss injection. The population most likely to be prescribed these medications overlaps almost entirely with the population at highest risk of undiagnosed MASLD.

You should discuss liver monitoring with your GP if you are starting a weight loss injection and:

• Have type 2 diabetes
• Have obesity (BMI above 30) or significant central abdominal fat
• Have had elevated liver enzymes (ALT, AST, GGT) on any previous blood test
• Have a family history of liver disease
• Drink alcohol regularly
• Have not had liver function tests in the past two years

The monitoring pathway is straightforward: a routine blood panel allows FIB-4 calculation. If indeterminate, liver elastography provides the next level of assessment.

Weight loss injections increase the risk of gallstone formation. A systematic review of 76 studies found GLP-1 medications increase the risk of gallstones by 27% and gallbladder inflammation by 36%.

Because the gallbladder sits directly beneath the liver and shares the biliary drainage system, gallbladder disease on weight loss injections can produce liver enzyme elevations that may be confused with liver disease progression.

Symptoms to watch for: right upper abdominal pain after eating, nausea, pain radiating to the right shoulder blade. Severe persistent pain with fever or jaundice requires urgent medical review.

Discuss any prior gallbladder history with your GP before starting a weight loss injection.

Ozempic (semaglutide) is indicated in Australia for type 2 diabetes. Wegovy (semaglutide 2.4mg) is approved for chronic weight management and reducing cardiovascular risk. Mounjaro (tirzepatide) was TGA-approved for weight management since September 2024.

The most significant recent regulatory change is the April 2026 TGA provisional approval of Wegovy specifically for MASH treatment — making it the first weight loss injection approved in Australia to treat liver disease directly.

If you are on a weight loss injection and want to understand your liver health baseline — or monitor your response to treatment — a liver elastography scan is the most informative non-invasive option available.

Liver elastography takes 10–15 minutes, involves no radiation, and is available at clinics across Australia. A growing number accept self-referred patients without a GP referral.

Find a liver elastography clinic near you →